Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years

Publication date: Available online 6 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Jiwon Oh, Anat Achiron, Elisabeth G. Celius, Christina Chambers, Joy Derwenskus, Virginia Devonshire, Kerstin Hellwig, George J. Hutton, Pamela McCombe, Marie Moore, David Rog, Jean-Raphael Schneider, Renata Faria Simm, Livia Sousa, Stephen G. Vincent, Luke Chung, Nadia Daizadeh, Colin Mitchell, D. Alastair S. Compston, CAMMS223, CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research